Inventor · disambiguated record
Mark J. Gilbert
Also filed as: GILBERT MARK · GILBERT MARK J
18 granted patents·11 pending applications·61 citations·filing 2013–2025
93Inventor score
Top patents by PatentIndex Score
29 records- 0192US11944647B2Articles of manufacture and methods for treatment using adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2022·Granted Apr 2, 2024·5 cites·20 claims
- 0292US11413310B2Articles of manufacture and methods for treatment using adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2018·Granted Aug 16, 2022·12 cites·55 claims
- 0390US10507219B2Methods and compositions for dosing in adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2015·Granted Dec 17, 2019·10 cites·38 claims
- 0486US12433885B2Procaspase combination therapy for glioblastomaUNIV ILLINOIS·Filed 2023·Granted Oct 7, 2025·0 cites·16 claims
- 0586US9421202B2Procaspase combination therapy for glioblastomaHERGENROTHER PAUL J·Filed 2013·Granted Aug 23, 2016·9 cites·20 claims
- 0686US9399035B2Procaspase 3 activation by combination therapyHERGENROTHER PAUL J·Filed 2013·Granted Jul 26, 2016·8 cites·5 claims
- 0784US10888560B2Procaspase 3 activation by combination therapyUNIV ILLINOIS·Filed 2018·Granted Jan 12, 2021·1 cites·10 claims
- 0884US9592229B2Potent anticancer activity via dual compound activationUNIV ILLINOIS·Filed 2013·Granted Mar 14, 2017·8 cites·21 claims
- 0983US11815514B2Methods and compositions related to toxicity associated with cell therapyJUNO THERAPEUTICS INC·Filed 2016·Granted Nov 14, 2023·2 cites·31 claims
- 1083US11633426B2Methods and compositions for dosing in adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2019·Granted Apr 25, 2023·1 cites·43 claims
- 1183US11266739B2Methods and compositions for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2015·Granted Mar 8, 2022·2 cites·45 claims
- 1283US2025312446A1Methods and compositions for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1382US2024066122A1Methods and compositions for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1478US2024115612A1Articles of manufacture and methods for treatment using adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1577US10874666B2Procaspase combination therapy for glioblastomaUNIV ILLINOIS·Filed 2018·Granted Dec 29, 2020·1 cites·12 claims
- 1677US2024082177A1Use of cysteamine and derivatives thereof to suppress tumor metastasesMESHABERASE LLC·Filed 2023·Application pending·0 cites
- 1775US10085978B2Procaspase combination therapy for glioblastomaUNIV ILLINOIS·Filed 2016·Granted Oct 2, 2018·1 cites·10 claims
- 1875US2022280642A1Methods and compositions for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1975US2023285463A1Methods and compositions for dosing in adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2074US11844798B2Procaspase combination therapy for glioblastomaUNIV ILLINOIS·Filed 2020·Granted Dec 19, 2023·0 cites·6 claims
- 2174US11833147B2Procaspase 3 activation by combination therapyUNIV ILLINOIS·Filed 2021·Granted Dec 5, 2023·0 cites·6 claims
- 2274US10085977B2Procaspase 3 activation by combination therapyUNIV ILLINOIS·Filed 2016·Granted Oct 2, 2018·1 cites·18 claims
- 2372US2024103012A1Methods and compositions related to toxicity associated with cell therapyJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2469US11844769B2Use of cysteamine and derivatives thereof to suppress tumor metastasesMESHABERASE LLC·Filed 2021·Granted Dec 19, 2023·0 cites·13 claims
- 2558US2025197471A1Methods for the treatment of b cell malignancies using adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2646US2022088070A1Methods for treatment using adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2745US2020016199A1Methods for the treatment of b cell malignancies using adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2844US2021198372A1Methods for dosing and for modulation of genetically engineered cellsJUNO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2939US12163952B2Determining toxicity risk in CAR T-cell therapyJUNO THERAPEUTICS INC·Filed 2018·Granted Dec 10, 2024·0 cites·28 claims
Join the waitlist — get patent alerts
Get an alert when Mark J. Gilbert files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →